Victorinox AG recently named Ulrich Wohn as president of its North American subsidiary, Victorinox Swiss Army Inc.
The company is headquartered in Switzerland but has offices in Monroe.
Wohn will report to Global CEO Carl Elsener, the great-great-grandson of the inventor of the Swiss Army Knife, company founder Karl Elsener I.
The company is also well-known for its cutlery, watches, travel gear and fragrances.
Carl Elsener said he is looking forward to working with Wohn to strengthen the company’s business in North America.
“His proven track record in both B2C and B2B and acute understanding of the North American market will allow us to push our business forward and continue to strengthen our brand with focused and sustainable strategies,” Elsener said.
Wohn most recently served as managing director of Bang & Olufsen North America.
“I have been a customer and fan of Victorinox my entire life and am thrilled to now work with such an iconic brand,” Wohn said.
*****
New Haven biopharma appoints two executives
Lisa Delfini
Trevi Therapeutics Inc., a New Haven-based clinical-stage biopharmaceutical company, has named Lisa Delfini as chief financial officer and Danine Summers as vice president, medical affairs.
Delfini will lead the company’s accounting and finance operations. Summers will be responsible for educating the medical community on its product data and development programs.
Jennifer L. Good, president and CEO, said their knowledge and experience “will be instrumental” as the company prepares for its next stage of growth.
Delfini joins Trevi with 30 years of experience in the financial sector, including positions with companies such as Marcum LLP and General Electric.
Danine Summers
Before joining Trevi, Summers had senior management roles in medical affairs and marketing at companies such as Anacor Pharmaceuticals, Menlo Therapeutics, Medicis Pharmaceutical and Roche Pharmaceuticals.
Trevi, founded in 2011, is focused on the development and commercialization of the investigational therapy Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease.
*****
Bioasis Technologies Inc. names new preclinical program manager
Bioasis Technologies Inc., a New Haven-based biotech, has a new preclinical program manager.
Jeffrey Sprouse brings over 20 years of drug discovery experience to his new role at Bioasis, according to an announcement.
Sprouse was trained as a neuropharmacologist, and he has had leadership roles at companies such as Pfizer. Since 2010, Sprouse has served as an industry consultant, managing all aspects of preclinical programs.
Bioasis is a pre-clinical, research-stage biopharmaceutical company. It is developing drugs that can bridge the brain’s filtering mechanism, known as the blood-brain barrier. It is focused on treating central nervous system disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
